

Richard W Compans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8311061/publications.pdf>

Version: 2024-02-01

375
papers

27,808
citations

4641

85
h-index

10708

138
g-index

383
all docs

383
docs citations

383
times ranked

16585
citing authors

#	ARTICLE	IF	CITATIONS
1	Programming the magnitude and persistence of antibody responses with innate immunity. <i>Nature</i> , 2011, 470, 543-547.	13.7	847
2	Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. <i>Virology</i> , 1974, 61, 397-410.	1.1	779
3	Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. <i>Journal of Experimental Medicine</i> , 2011, 208, 181-193.	4.2	775
4	Dissolving polymer microneedle patches for influenza vaccination. <i>Nature Medicine</i> , 2010, 16, 915-920.	15.2	754
5	Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. <i>Nature Immunology</i> , 2010, 11, 1127-1135.	7.0	644
6	Identification of -Dystroglycan as a Receptor for Lymphocytic Choriomeningitis Virus and Lassa Fever Virus. , 1998, 282, 2079-2081.		609
7	The three-dimensional structure of canine parvovirus and its functional implications. <i>Science</i> , 1991, 251, 1456-1464.	6.0	496
8	Isolation of paramyxovirus glycoproteins. Association of both hemagglutinating and neuraminidase activities with the larger SV5 glycoprotein. <i>Virology</i> , 1972, 50, 640-652.	1.1	378
9	Influenza virus proteins. <i>Virology</i> , 1970, 42, 880-889.	1.1	367
10	Influenza virus structural and nonstructural proteins in infected cells and their plasma membranes. <i>Virology</i> , 1971, 46, 830-843.	1.1	358
11	Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. <i>Journal of Virology</i> , 1995, 69, 1099-1106.	1.5	331
12	Inhibition of Influenza Virus Replication in Tissue Culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): Mechanism of Action. <i>Journal of General Virology</i> , 1976, 33, 159-163.	1.3	315
13	The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. <i>Lancet, The</i> , 2017, 390, 649-658.	6.3	309
14	Protection against vaginal SIV transmission with microencapsulated vaccine. <i>Science</i> , 1993, 260, 1323-1327.	6.0	295
15	Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus. <i>Journal of Virology</i> , 2007, 81, 3514-3524.	1.5	279
16	Alpha/Beta Interferons Potentiate Virus-Induced Apoptosis through Activation of the FADD/Caspase-8 Death Signaling Pathway. <i>Journal of Virology</i> , 2000, 74, 1513-1523.	1.5	269
17	An electron microscopic study of moderate and virulent virus-cell interactions of the parainfluenza virus SV5. <i>Virology</i> , 1966, 30, 411-426.	1.1	251
18	Original Antigenic Sin Responses to Influenza Viruses. <i>Journal of Immunology</i> , 2009, 183, 3294-3301.	0.4	234

#	ARTICLE	IF	CITATIONS
19	Structure of the Ribonucleoprotein of Influenza Virus. <i>Journal of Virology</i> , 1972, 10, 795-800.	1.5	233
20	Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses. <i>Journal of Virology</i> , 1992, 66, 1528-1534.	1.5	220
21	Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. <i>Journal of Controlled Release</i> , 2010, 142, 187-195.	4.8	217
22	The membrane structure of lipid-containing viruses. <i>BBA - Biomembranes</i> , 1974, 344, 51-94.	7.9	210
23	Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 757-761.	3.3	206
24	Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 3987-3991.	3.3	200
25	Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7968-7973.	3.3	190
26	Proteins of Vesicular Stomatitis Virus and of Phenotypically Mixed Vesicular Stomatitis Virus-Simian Virus 5 Virions. <i>Journal of Virology</i> , 1971, 8, 722-729.	1.5	180
27	The M1 and M2 Proteins of Influenza A Virus Are Important Determinants in Filamentous Particle Formation. <i>Virology</i> , 1998, 240, 127-137.	1.1	179
28	Reproduction of Paramyxoviruses. , 1975, , 95-178.		174
29	Proteins and Glycoproteins of Paramyxoviruses: a Comparison of Simian Virus 5, Newcastle Disease Virus, and Sendai Virus. <i>Journal of Virology</i> , 1971, 7, 47-52.	1.5	174
30	Inhibition of influenza infection by glutathione. <i>Free Radical Biology and Medicine</i> , 2003, 34, 928-936.	1.3	173
31	Effects of glucosamine, 2-deoxyglucose, and tunicamycin on glycosylation, sulfation, and assembly of influenza viral proteins. <i>Virology</i> , 1978, 84, 303-319.	1.1	168
32	Transdermal Influenza Immunization with Vaccine-Coated Microneedle Arrays. <i>PLoS ONE</i> , 2009, 4, e4773.	1.1	160
33	Influenza virus hemagglutinin expression is polarized in cells infected with recombinant SV40 viruses carrying cloned hemagglutinin DNA. <i>Cell</i> , 1983, 33, 435-443.	13.5	148
34	Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal Immunization. <i>Journal of Virology</i> , 2008, 82, 1350-1359.	1.5	147
35	Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. <i>Nature Communications</i> , 2018, 9, 359.	5.8	147
36	Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus. <i>PLoS Pathogens</i> , 2012, 8, e1003065.	2.1	146

#	ARTICLE	IF	CITATIONS
37	Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. <i>Journal of Virology</i> , 1992, 66, 3971-3975.	1.5	145
38	Influenza virus proteins. <i>Virology</i> , 1973, 51, 56-70.	1.1	142
39	A Specific Labeling Procedure for Proteins on the Outer Surface of Membranes. <i>Journal of Biological Chemistry</i> , 1972, 247, 6432-6437.	1.6	142
40	Cell Fusion Activity of the Simian Immunodeficiency Virus Envelope Protein Is Modulated by the Intracytoplasmic Domain. <i>Virology</i> , 1993, 197, 255-264.	1.1	140
41	Oral Immunization with Influenza Virus in Biodegradable Microspheres. <i>Journal of Infectious Diseases</i> , 1993, 167, 84-90.	1.9	140
42	Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus. <i>Molecular Therapy</i> , 2013, 21, 485-492.	3.7	138
43	Nucleocapsid Protein Subunits of Simian Virus 5, Newcastle Disease Virus, and Sendai Virus. <i>Journal of Virology</i> , 1970, 6, 677-684.	1.5	138
44	An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. <i>Virology</i> , 1969, 39, 499-515.	1.1	136
45	Respiratory syncytial virus matures at the apical surfaces of polarized epithelial cells. <i>Journal of Virology</i> , 1995, 69, 2667-2673.	1.5	134
46	Proteolytic cleavage of the hemagglutinin polypeptide of influenza virus. Function of the uncleaved polypeptide HA. <i>Virology</i> , 1973, 52, 199-212.	1.1	133
47	Peptides Corresponding to the Heptad Repeat Sequence of Human Parainfluenza Virus Fusion Protein Are Potent Inhibitors of Virus Infection. <i>Virology</i> , 1996, 223, 103-112.	1.1	128
48	Influenza vaccines based on virus-like particles. <i>Virus Research</i> , 2009, 143, 140-146.	1.1	123
49	Host cell dependence of viral morphology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 5746-5751.	3.3	119
50	A specific labeling procedure for proteins on the outer surface of membranes. <i>Journal of Biological Chemistry</i> , 1972, 247, 6432-7.	1.6	119
51	Incorporation of Membrane-Anchored Flagellin into Influenza Virus-Like Particles Enhances the Breadth of Immune Responses. <i>Journal of Virology</i> , 2008, 82, 11813-11823.	1.5	118
52	Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization. <i>Journal of Virology</i> , 2010, 84, 7760-7769.	1.5	118
53	Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice. <i>Journal of Infectious Diseases</i> , 2011, 204, 987-995.	1.9	117
54	Polarity of influenza and vesicular stomatitis virus maturation in MDCK cells: lack of a requirement for glycosylation of viral glycoproteins.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1979, 76, 6430-6434.	3.3	115

#	ARTICLE	IF	CITATIONS
55	Identification of the spike proteins of Rous sarcoma virus. <i>Virology</i> , 1971, 46, 485-489.	1.1	114
56	Phenotypic Mixing of Envelope Proteins of the Parainfluenza Virus SV5 and Vesicular Stomatitis Virus. <i>Journal of Virology</i> , 1970, 5, 609-616.	1.5	112
57	Improved influenza vaccination in the skin using vaccine coated microneedles. <i>Vaccine</i> , 2009, 27, 6932-6938.	1.7	110
58	Nontemplated bases at the 5' ends of tacaribe virus mRNAs. <i>Virology</i> , 1990, 174, 53-59.	1.1	108
59	Location of the Glycoprotein in the Membrane of Sindbis Virus. <i>Nature: New Biology</i> , 1971, 229, 114-116.	4.5	107
60	Enhanced Memory Responses to Seasonal H1N1 Influenza Vaccination of the Skin with the Use of Vaccine-Coated Microneedles. <i>Journal of Infectious Diseases</i> , 2010, 201, 190-198.	1.9	107
61	Stability of influenza vaccine coated onto microneedles. <i>Biomaterials</i> , 2012, 33, 3756-3769.	5.7	106
62	Spin-Label Electron Spin Resonance Study of the Lipid-Containing Membrane of Influenza Virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1971, 68, 2579-2583.	3.3	104
63	Immunity to Pre-1950 H1N1 Influenza Viruses Confers Cross-Protection against the Pandemic Swine-Origin 2009 A (H1N1) Influenza Virus. <i>Journal of Immunology</i> , 2010, 185, 1642-1649.	0.4	104
64	Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective Immunity. <i>PLoS ONE</i> , 2011, 6, e14538.	1.1	104
65	Host cell- and virus strain-dependent differences in oligosaccharides of hemagglutinin glycoproteins of influenza A viruses. <i>Virology</i> , 1979, 95, 8-23.	1.1	102
66	Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. <i>Virology</i> , 1990, 176, 48-57.	1.1	102
67	Enhanced Immunogenicity of Stabilized Trimeric Soluble Influenza Hemagglutinin. <i>PLoS ONE</i> , 2010, 5, e12466.	1.1	102
68	An electron microscopic study of the presence or absence of neuraminic acid in enveloped viruses. <i>Virology</i> , 1970, 42, 1158-1162.	1.1	101
69	Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.. <i>Journal of Clinical Investigation</i> , 1990, 86, 1142-1150.	3.9	101
70	Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. <i>Journal of Controlled Release</i> , 2010, 147, 326-332.	4.8	99
71	Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. <i>Vaccine</i> , 2010, 28, 4103-4112.	1.7	99
72	Long-term stability of influenza vaccine in a dissolving microneedle patch. <i>Drug Delivery and Translational Research</i> , 2017, 7, 195-205.	3.0	98

#	ARTICLE	IF	CITATIONS
73	The P gene of human parainfluenza virus type 1 encodes P and C proteins but not a cysteine-rich V protein. <i>Journal of Virology</i> , 1991, 65, 3406-3410.	1.5	98
74	Virus Infection of Polarized Epithelial Cells. <i>Advances in Virus Research</i> , 1993, 42, 187-247.	0.9	97
75	An Infectious Clone of the West Nile Flavivirus. <i>Virology</i> , 2001, 281, 294-304.	1.1	97
76	Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. <i>Virology</i> , 2006, 351, 260-270.	1.1	96
77	The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 9871-9875.	3.3	94
78	H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation. <i>PLoS Pathogens</i> , 2017, 13, e1006757.	2.1	94
79	Assembly of SIV Virus-like Particles Containing Envelope Proteins Using a Baculovirus Expression System. <i>Virology</i> , 1995, 214, 50-58.	1.1	93
80	Influenza virus inhibits ENaC and lung fluid clearance. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 287, L366-L373.	1.3	93
81	Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles. <i>PLoS ONE</i> , 2009, 4, e4667.	1.1	93
82	Release of simian virus 40 virions from epithelial cells is polarized and occurs without cell lysis. <i>Journal of Virology</i> , 1989, 63, 2278-2288.	1.5	93
83	Inactivation of Human Immunodeficiency Virus Type 1 by Porphyrins. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3917-3925.	1.4	92
84	Ebola Vaccination Using a DNA Vaccine Coated on PLGA-PLL/PGA Nanoparticles Administered Using a Microneedle Patch. <i>Advanced Healthcare Materials</i> , 2017, 6, 1600750.	3.9	92
85	Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin. <i>PLoS ONE</i> , 2009, 4, e7152.	1.1	92
86	Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine. <i>AAPS PharmSciTech</i> , 2010, 11, 1193-1201.	1.5	91
87	Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice. <i>PLoS ONE</i> , 2010, 5, e9161.	1.1	91
88	Stability Kinetics of Influenza Vaccine Coated onto Microneedles During Drying and Storage. <i>Pharmaceutical Research</i> , 2011, 28, 135-144.	1.7	91
89	Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. <i>Scientific Reports</i> , 2012, 2, 357.	1.6	91
90	Parainfluenza Virus Surface Projections: Glycoproteins with Haemagglutinin and Neuraminidase Activities. <i>Journal of General Virology</i> , 1971, 11, 53-58.	1.3	90

#	ARTICLE	IF	CITATIONS
91	Murine model for evaluation of protective immunity to influenza virus. <i>Vaccine</i> , 1993, 11, 55-60.	1.7	90
92	Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. <i>Journal of Virology</i> , 1994, 68, 463-468.	1.5	90
93	Glycopeptide components of influenza viral glycoproteins. <i>Virology</i> , 1978, 86, 432-442.	1.1	89
94	Transcutaneous immunization with inactivated influenza virus induces protective immune responses. <i>Vaccine</i> , 2006, 24, 6110-6119.	1.7	87
95	Regulation of the Late Events in Flavivirus Protein Processing and Maturation. <i>Virology</i> , 1993, 192, 38-51.	1.1	86
96	Protection against lethal challenge by Ebola virus-like particles produced in insect cells. <i>Virology</i> , 2009, 383, 12-21.	1.1	84
97	Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. <i>Virology</i> , 2010, 405, 165-175.	1.1	84
98	Isolation and structural analysis of influenza C virion glycoproteins. <i>Virology</i> , 1981, 113, 439-451.	1.1	83
99	Effect of Antibody to Neuraminidase on the Maturation and Hemagglutinating Activity of an Influenza A ₂ Virus. <i>Journal of Virology</i> , 1969, 4, 528-534.	1.5	83
100	Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. <i>Drug Delivery and Translational Research</i> , 2015, 5, 360-371.	3.0	82
101	Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection. <i>PLoS ONE</i> , 2010, 5, e13972.	1.1	82
102	Effect of Adjuvants on Responses to Skin Immunization by Microneedles Coated with Influenza Subunit Vaccine. <i>PLoS ONE</i> , 2012, 7, e41501.	1.1	81
103	Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7758-E7767.	3.3	81
104	Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles. <i>Journal of Virology</i> , 2007, 81, 10869-10878.	1.5	80
105	Entry and Release of Measles Virus Are Polarized in Epithelial Cells. <i>Virology</i> , 1995, 210, 91-99.	1.1	79
106	Effects of hexose starvation and the role of sialic acid in influenza virus release. <i>Virology</i> , 1983, 125, 324-334.	1.1	78
107	Structure of the influenza C glycoprotein gene as determined from cloned DNA. <i>Virus Research</i> , 1984, 1, 281-296.	1.1	78
108	Effects of Cytoplasmic Domain Length on Cell Surface Expression and Syncytium-Forming Capacity of the Simian Immunodeficiency Virus Envelope Glycoprotein. <i>Virology</i> , 1994, 203, 8-19.	1.1	78

#	ARTICLE	IF	CITATIONS
109	Effects of Antibody to the Influenza A Virus M2 Protein on M2 Surface Expression and Virus Assembly. <i>Virology</i> , 1995, 212, 411-421.	1.1	78
110	A target site for template-based design of measles virus entry inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5628-5633.	3.3	78
111	A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. <i>Vaccine</i> , 2008, 26, 3352-3361.	1.7	77
112	A precursor glycoprotein in influenza C virus. <i>Virology</i> , 1979, 99, 49-56.	1.1	76
113	The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing. <i>Virology</i> , 1990, 179, 827-833.	1.1	75
114	Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. <i>Vaccine</i> , 2007, 25, 272-282.	1.7	75
115	Proteolytic Cleavage of Subunits of the Nucleocapsid of the Paramyxovirus Simian Virus 5. <i>Journal of Virology</i> , 1974, 14, 1253-1261.	1.5	75
116	Nucleotide sequence conservation at the 3' termini of the virion RNA species of new World and Old World arenaviruses. <i>Virology</i> , 1982, 121, 200-203.	1.1	74
117	Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte-Macrophage Colony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles. <i>Journal of Virology</i> , 2007, 81, 1083-1094.	1.5	73
118	Virus-like particles as universal influenza vaccines. <i>Expert Review of Vaccines</i> , 2012, 11, 995-1007.	2.0	73
119	Protective Effect of Ginseng Polysaccharides on Influenza Viral Infection. <i>PLoS ONE</i> , 2012, 7, e33678.	1.1	73
120	Induction of CD4+ T-Cell-Independent Immunoglobulin Responses by Inactivated Influenza Virus. <i>Journal of Virology</i> , 2000, 74, 4999-5005.	1.5	72
121	Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. <i>Journal of Controlled Release</i> , 2014, 178, 1-7.	4.8	72
122	Microneedle Vaccination with Stabilized Recombinant Influenza Virus Hemagglutinin Induces Improved Protective Immunity. <i>Vaccine Journal</i> , 2011, 18, 647-654.	3.2	71
123	Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 81, 239-247.	2.0	71
124	Processing of the intracellular form of the west Nile virus capsid protein by the viral NS2B-NS3 protease: an in vitro study. <i>Journal of Virology</i> , 1994, 68, 5765-5771.	1.5	71
125	Role of Actin Microfilaments in Black Creek Canal Virus Morphogenesis. <i>Journal of Virology</i> , 1998, 72, 2865-2870.	1.5	70
126	Distinct carbohydrate components of influenza virus glycoproteins in smooth and rough cytoplasmic membranes. <i>Virology</i> , 1973, 55, 541-545.	1.1	69

#	ARTICLE	IF	CITATIONS
127	Organization of the lipid phase in viral membranes. Effects of independent variation of the lipid and the protein composition. <i>Biochemistry</i> , 1973, 12, 4498-4502.	1.2	69
128	Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. <i>Journal of Controlled Release</i> , 2013, 166, 159-171.	4.8	69
129	Human immunodeficiency virus-like particles activate multiple types of immune cells. <i>Virology</i> , 2007, 362, 331-341.	1.1	68
130	Microneedle Delivery of H5N1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in Mice. <i>Vaccine Journal</i> , 2010, 17, 1381-1389.	3.2	68
131	DNA Vaccination in the Skin Using Microneedles Improves Protection Against Influenza. <i>Molecular Therapy</i> , 2012, 20, 1472-1480.	3.7	68
132	Structure and Cytopathic Effects of Nelson Bay Virus. <i>Journal of Virology</i> , 1970, 6, 100-106.	1.5	67
133	Emergence and Evolution of Avian H5N2 Influenza Viruses in Chickens in Taiwan. <i>Journal of Virology</i> , 2014, 88, 5677-5686.	1.5	66
134	Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches. <i>Pharmaceutical Research</i> , 2016, 33, 868-878.	1.7	66
135	Isolation and characterization of the nonglycosylated membrane protein and a nucleocapsid complex from the paramyxovirus SV5. <i>Virology</i> , 1975, 67, 365-374.	1.1	65
136	Nonpeptide Inhibitors of Measles Virus Entry. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5080-5092.	2.9	65
137	Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. <i>Antiviral Research</i> , 2010, 88, 244-247.	1.9	65
138	Local Response to Microneedle-Based Influenza Immunization in the Skin. <i>MBio</i> , 2012, 3, e00012-12.	1.8	64
139	Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. <i>Vaccine</i> , 2010, 28, 6104-6113.	1.7	63
140	Sin nombre virus glycoprotein trafficking. <i>Virology</i> , 2003, 308, 48-63.	1.1	62
141	Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus Conjugated with Cholera Toxin Subunit B. <i>Journal of Virology</i> , 2003, 77, 9823-9830.	1.5	62
142	Enhanced Mucosal Immune Responses to HIV Virus-Like Particles Containing a Membrane-Anchored Adjuvant. <i>MBio</i> , 2011, 2, e00328-10.	1.8	62
143	Viral Membranes: Model Systems for Studying Biological Membrane. <i>CRC Critical Reviews in Biochemistry</i> , 1979, 6, 165-217.	2.0	61
144	Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. <i>Virology</i> , 2012, 430, 127-135.	1.1	61

#	ARTICLE	IF	CITATIONS
145	Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. <i>Antiviral Research</i> , 2013, 99, 328-335.	1.9	61
146	Tetanus vaccination with a dissolving microneedle patch confers protective immune responses in pregnancy. <i>Journal of Controlled Release</i> , 2016, 236, 47-56.	4.8	61
147	Expression and characterization of a functional human immunodeficiency virus envelope glycoprotein in insect cells. <i>Virology</i> , 1990, 176, 575-586.	1.1	60
148	Palmitoylation of the Murine Leukemia Virus Envelope Protein Is Critical for Lipid Raft Association and Surface Expression. <i>Journal of Virology</i> , 2002, 76, 11845-11852.	1.5	60
149	Universal Influenza Vaccines, a Dream to Be Realized Soon. <i>Viruses</i> , 2014, 6, 1974-1991.	1.5	60
150	Kinetics of Immune Responses to Influenza Virus-Like Particles and Dose-Dependence of Protection with a Single Vaccination. <i>Journal of Virology</i> , 2009, 83, 4489-4497.	1.5	59
151	Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch. <i>Vaccine Journal</i> , 2013, 20, 1433-1439.	3.2	59
152	STUDIES ON PNEUMONIA VIRUS OF MICE (PVM) IN CELL CULTURE. <i>Journal of Experimental Medicine</i> , 1967, 126, 267-276.	4.2	58
153	Effect of membrane protein on lipid bilayer structure: a spin-label electron spin resonance study of vesicular stomatitis virus. <i>Biochemistry</i> , 1976, 15, 2356-2360.	1.2	58
154	Current options for vaccine delivery systems by mucosal routes. <i>Journal of Controlled Release</i> , 1997, 48, 243-257.	4.8	58
155	Pause on Avian Flu Transmission Research. <i>Science</i> , 2012, 335, 400-401.	6.0	58
156	Golgi complex localization of the Punta Toro virus G2 protein requires its association with the G1 protein. <i>Virology</i> , 1991, 183, 351-365.	1.1	57
157	Synthesis of mumps virus polypeptides in infected vero cells. <i>Virology</i> , 1982, 119, 430-438.	1.1	56
158	Function of the KKXX Motif in Endoplasmic Reticulum Retrieval of a Transmembrane Protein Depends on the Length and Structure of the Cytoplasmic Domain. <i>Journal of Biological Chemistry</i> , 1998, 273, 950-956.	1.6	56
159	The nucleic acid of the parainfluenza virus SV5. <i>Virology</i> , 1968, 35, 289-296.	1.1	55
160	Nonpolarized expression of a secreted murine leukemia virus glycoprotein in polarized epithelial cells. <i>Cell</i> , 1986, 47, 1053-1059.	13.5	55
161	Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. <i>Journal of Controlled Release</i> , 2013, 172, 579-588.	4.8	55
162	Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 473-482.	1.7	55

#	ARTICLE	IF	CITATIONS
163	Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. <i>Virology</i> , 2005, 331, 20-32.	1.1	54
164	Serological Memory and Long-term Protection to Novel H1N1 Influenza Virus After Skin Vaccination. <i>Journal of Infectious Diseases</i> , 2011, 204, 582-591.	1.9	54
165	Reproduction of Myxoviruses. , 1975, , 179-252.		53
166	Time Course of Synthesis and Assembly of Influenza Virus Proteins. <i>Journal of Virology</i> , 1974, 14, 1083-1091.	1.5	53
167	Mutations in the Putative HR-C Region of the Measles Virus F 2 Glycoprotein Modulate Syncytium Formation. <i>Journal of Virology</i> , 2003, 77, 4181-4190.	1.5	52
168	Design of a Small-Molecule Entry Inhibitor with Activity against Primary Measles Virus Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3755-3761.	1.4	52
169	Intracellular accumulation of punta toro virus glycoproteins expressed from cloned cDNA. <i>Virology</i> , 1988, 167, 251-260.	1.1	51
170	Molecular domains involved in oligomerization of the friend murine leukemia virus envelope glycoprotein. <i>Virology</i> , 1991, 185, 710-720.	1.1	51
171	Incorporation of sulfate into influenza virus glycoproteins. <i>Virology</i> , 1975, 66, 151-160.	1.1	50
172	Structural proteins of tacaribe and tamiami virions. <i>Virology</i> , 1977, 83, 84-95.	1.1	49
173	Oligopeptide Inhibitors of HIV-Induced Syncytium Formation. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 1289-1296.	0.5	49
174	Production and Characterization of Simian-Human Immunodeficiency Virus-Like Particles. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 227-236.	0.5	49
175	Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. <i>Virology</i> , 2003, 313, 502-513.	1.1	49
176	Association of the internal membrane protein with the lipid bilayer in influenza virus. A study with the fluorescent probe 12-(9-anthroyl)-stearic acid. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1974, 332, 341-349.	1.4	48
177	Immune response to human influenza virus hemagglutinin expressed in <i>Escherichia coli</i> . <i>Gene</i> , 1983, 21, 273-284.	1.0	48
178	Two Domains That Control Prefusion Stability and Transport Competence of the Measles Virus Fusion Protein. <i>Journal of Virology</i> , 2006, 80, 1524-1536.	1.5	48
179	Human immunodeficiency virus type 2 envelope glycoprotein: Differential CD4 interactions of soluble gp120 versus the assembled envelope complex. <i>Virology</i> , 1992, 187, 233-241.	1.1	47
180	Hantavirus Nucleocapsid Protein Is Expressed as a Membrane-Associated Protein in the Perinuclear Region. <i>Journal of Virology</i> , 2001, 75, 1808-1815.	1.5	47

#	ARTICLE	IF	CITATIONS
181	Host Responses from Innate to Adaptive Immunity after Vaccination: Molecular and Cellular Events. <i>Molecules and Cells</i> , 2009, 27, 5-14.	1.0	47
182	Compartmentalization within the Common Mucosal Immune System. <i>Advances in Experimental Medicine and Biology</i> , 1995, 371A, 97-101.	0.8	47
183	The length of the helical nucleocapsid of Newcastle disease virus. <i>Virology</i> , 1967, 33, 344-346.	1.1	46
184	Supplementation of Influenza Split Vaccines with Conserved M2 Ectodomains Overcomes Strain Specificity and Provides Long-term Cross Protection. <i>Molecular Therapy</i> , 2014, 22, 1364-1374.	3.7	46
185	Hemagglutination-Inhibition: Rapid Assay for Neuraminic Acid-Containing Viruses. <i>Journal of Virology</i> , 1974, 14, 1307-1309.	1.5	46
186	The cellular site of sulfation of influenza viral glycoproteins. <i>Virology</i> , 1977, 79, 381-392.	1.1	45
187	Secretion of a Truncated Form of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein. <i>Virology</i> , 1993, 193, 510-514.	1.1	45
188	A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. <i>American Journal of Gastroenterology</i> , 1998, 93, 1931-1937.	0.2	45
189	Enhancement of Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2003, 77, 3615-3623.	1.5	45
190	Enhanced Influenza Virus-Like Particle Vaccines Containing the Extracellular Domain of Matrix Protein 2 and a Toll-Like Receptor Ligand. <i>Vaccine Journal</i> , 2012, 19, 1119-1125.	3.2	45
191	Regulation of Fusion Activity by the Cytoplasmic Domain of a Paramyxovirus F Protein. <i>Virology</i> , 2002, 301, 322-333.	1.1	44
192	Influenza Virus-Specific Neutralizing IgM Antibodies Persist for a Lifetime. <i>Vaccine Journal</i> , 2014, 21, 1481-1489.	3.2	44
193	Biosynthesis of the oligosaccharides of influenza viral glycoproteins. <i>Virology</i> , 1979, 93, 31-47.	1.1	43
194	Less Is More: Ebola Virus Surface Glycoprotein Expression Levels Regulate Virus Production and Infectivity. <i>Journal of Virology</i> , 2015, 89, 1205-1217.	1.5	43
195	Isolation and Properties of an RNA Polymerase from Influenza Virus-Infected Cells. <i>Journal of Virology</i> , 1973, 11, 441-448.	1.5	43
196	Structural components of mouse mammary tumor virus I. Polypeptides of the virion. <i>Virology</i> , 1977, 76, 751-766.	1.1	42
197	Structural Features of Paramyxovirus F Protein Required for Fusion Initiation. <i>Biochemistry</i> , 2003, 42, 6645-6655.	1.2	42
198	Mutations in the Cytoplasmic Domain of a Paramyxovirus Fusion Glycoprotein Rescue Syncytium Formation and Eliminate the Hemagglutinin-Neuraminidase Protein Requirement for Membrane Fusion. <i>Journal of Virology</i> , 2003, 77, 167-178.	1.5	42

#	ARTICLE	IF	CITATIONS
199	MyD88 Plays an Essential Role in Inducing B Cells Capable of Differentiating into Antibody-Secreting Cells after Vaccination. <i>Journal of Virology</i> , 2011, 85, 11391-11400.	1.5	42
200	Virus-like particle and DNA-based candidate AIDS vaccines. <i>Vaccine</i> , 2003, 21, 638-643.	1.7	41
201	Intranasal Immunization with Inactivated Influenza Virus Enhances Immune Responses to Coadministered Simian-Human Immunodeficiency Virus-Like Particle Antigens. <i>Journal of Virology</i> , 2004, 78, 9624-9632.	1.5	40
202	Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. <i>Antiviral Research</i> , 2009, 84, 215-224.	1.9	40
203	Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	40
204	Glycosylation sites of influenza viral glycoproteins Tryptic glycopeptides from the A/WSN (H0N1) hemagglutinin glycoprotein. <i>Virology</i> , 1980, 107, 208-221.	1.1	39
205	Characterization of the rna associated with influenza A cytoplasmic inclusions and the interaction of NS1 protein with RNA. <i>Virology</i> , 1981, 110, 87-97.	1.1	39
206	Effect of tunicamycin on the replication of sendai virus. <i>Virology</i> , 1982, 119, 474-487.	1.1	39
207	Intranasal Immunization of Hamsters with Envelope Glycoproteins of Human Parainfluenza Virus Type 3. <i>Journal of Infectious Diseases</i> , 1988, 157, 648-654.	1.9	39
208	Assembly and Release of SIV Env Proteins with Full-Length or Truncated Cytoplasmic Domains. <i>Virology</i> , 1996, 221, 22-33.	1.1	39
209	Palmitoylation of the Murine Leukemia Virus Envelope Glycoprotein Transmembrane Subunits. <i>Virology</i> , 1996, 221, 87-97.	1.1	39
210	Induction of HIV Neutralizing Antibodies against the MPER of the HIV Envelope Protein by HA/gp41 Chimeric Protein-Based DNA and VLP Vaccines. <i>PLoS ONE</i> , 2011, 6, e14813.	1.1	39
211	Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property. <i>Virus Research</i> , 1989, 12, 169-180.	1.1	38
212	Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. <i>Vaccine</i> , 2002, 20, 2537-2545.	1.7	38
213	Prevention of HIV-1 infection by phthalocyanines. <i>Antiviral Research</i> , 2003, 59, 99-109.	1.9	38
214	Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts. <i>Vaccine</i> , 2015, 33, 4675-4682.	1.7	38
215	Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza. <i>Journal of Controlled Release</i> , 2018, 276, 1-16.	4.8	38
216	A polarized human endometrial cell line that binds and transports polymeric IgA. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1995, 31, 196-206.	0.7	37

#	ARTICLE	IF	CITATIONS
217	Surface Stability and Immunogenicity of the Human Immunodeficiency Virus Envelope Glycoprotein: Role of the Cytoplasmic Domain. <i>Journal of Virology</i> , 2004, 78, 13409-13419.	1.5	36
218	Salmonella flagellin enhances mucosal immunity of avian influenza vaccine in chickens. <i>Veterinary Microbiology</i> , 2012, 157, 69-77.	0.8	36
219	The organization of the proteins of vesicular stomatitis virions: Labeling with pyridoxal phosphate. <i>Virology</i> , 1975, 66, 610-615.	1.1	35
220	Replication and morphogenesis of avian coronavirus in Vero cells and their inhibition by monensin. <i>Virus Research</i> , 1984, 1, 153-167.	1.1	35
221	Sialic acid is incorporated into influenza hemagglutinin glycoproteins in the absence of viral neuraminidase. <i>Virus Research</i> , 1985, 2, 61-68.	1.1	35
222	Sulfonated naphthyl porphyrins as agents against HIV-1. <i>Journal of Inorganic Biochemistry</i> , 2005, 99, 813-821.	1.5	35
223	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. <i>Scientific Reports</i> , 2016, 6, 24897.	1.6	35
224	Evidence for Cooperation between Murine Leukemia Virus Env Molecules in Mixed Oligomers. <i>Journal of Virology</i> , 1998, 72, 3432-3435.	1.5	35
225	Transmission Studies Resume for Avian Flu. <i>Science</i> , 2013, 339, 520-521.	6.0	34
226	Intracellular Interaction of Simian Immunodeficiency Virus Gag and Env Proteins. <i>Journal of Virology</i> , 1999, 73, 8138-8144.	1.5	34
227	Isolation and characterization of ribonucleoprotein substructures from Rous sarcoma virus. <i>Virology</i> , 1972, 50, 65-75.	1.1	33
228	Cell fusion induced by Nelson Bay Virus. <i>Virology</i> , 1982, 123, 312-322.	1.1	33
229	The NS and capsid genes determine the host range of porcine parvovirus. <i>Virology</i> , 1992, 187, 515-524.	1.1	33
230	Prevention of poxvirus infection by tetrapyrroles. <i>BMC Infectious Diseases</i> , 2003, 3, 9.	1.3	33
231	Targeting the Skin for Microneedle Delivery of Influenza Vaccine. <i>Advances in Experimental Medicine and Biology</i> , 2013, 785, 121-132.	0.8	33
232	Synthesis of Tacaribe viral proteins. <i>Virology</i> , 1979, 93, 369-376.	1.1	32
233	The env Protein of an Infectious Noncytopathic HIV-2 Is Deficient in Syncytium Formation. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 707-720.	0.5	32
234	Molecular Determinants of Golgi Retention in the Punta Toro Virus G1 Protein. <i>Archives of Biochemistry and Biophysics</i> , 1996, 336, 184-189.	1.4	32

#	ARTICLE	IF	CITATIONS
235	The Short Sendai Virus Leader Region Controls Induction of Programmed Cell Death. <i>Virology</i> , 1998, 243, 340-353.	1.1	32
236	Novel vaccines against influenza viruses. <i>Virus Research</i> , 2011, 162, 31-38.	1.1	32
237	Emerged HA and NA Mutants of the Pandemic Influenza H1N1 Viruses with Increasing Epidemiological Significance in Taipei and Kaohsiung, Taiwan, 2009-2010. <i>PLoS ONE</i> , 2012, 7, e31162.	1.1	32
238	Studies on the role of glycosylation in the functions and antigenic properties of influenza virus glycoproteins. <i>Virology</i> , 1983, 128, 77-91.	1.1	31
239	Effect of the Cytoplasmic Domain of the Simian Immunodeficiency Virus Envelope Protein on Incorporation of Heterologous Envelope Proteins and Sensitivity to Neutralization. <i>Journal of Virology</i> , 2000, 74, 8219-8225.	1.5	31
240	Prevention of HIV-1 infection by platinum triazines. <i>Antiviral Research</i> , 2005, 65, 57-67.	1.9	31
241	Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedles. <i>Procedia in Vaccinology</i> , 2010, 2, 17-21.	0.4	31
242	Host Responses in Human Skin After Conventional Intradermal Injection or Microneedle Administration of Virus-Like Particle Influenza Vaccine. <i>Advanced Healthcare Materials</i> , 2013, 2, 1401-1410.	3.9	31
243	Changes in Human Langerhans Cells Following Intradermal Injection of Influenza Virus-Like Particle Vaccines. <i>PLoS ONE</i> , 2010, 5, e12410.	1.1	30
244	Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. <i>Antiviral Research</i> , 2014, 111, 129-135.	1.9	30
245	Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 253-262.	1.7	30
246	Filamentous particle formation by human parainfluenza virus type 2. <i>Microbiology (United Kingdom)</i> , 2000, 81, 1305-1312.	0.7	30
247	Activation of Fusion by the SER Virus F Protein: a Low-pH-Dependent Paramyxovirus Entry Process. <i>Journal of Virology</i> , 2003, 77, 6520-6527.	1.5	29
248	Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection against 2009 H1N1 Pandemic Influenza. <i>Vaccine Journal</i> , 2011, 18, 2010-2017.	3.2	29
249	The Structure and Assembly of Influenza and Parainfluenza Viruses. , 1971, , 407-432.		29
250	Immunogenicity of low-pH treated whole viral influenza vaccine. <i>Virology</i> , 2011, 417, 196-202.	1.1	28
251	Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles. <i>PLoS ONE</i> , 2015, 10, e0134431.	1.1	28
252	Vesicular Stomatitis Virus G Protein Acquires pH-Independent Fusion Activity during Transport in a Polarized Endometrial Cell Line. <i>Journal of Virology</i> , 1999, 73, 10447-10457.	1.5	28

#	ARTICLE	IF	CITATIONS
253	Protection against filovirus infection: virus-like particle vaccines. <i>Expert Review of Vaccines</i> , 2008, 7, 333-344.	2.0	27
254	Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. <i>Vaccine</i> , 2008, 26, 1541-1551.	1.7	27
255	Analysis of the In Vitro Product of an RNA-Dependent RNA Polymerase Isolated from Influenza Virus-Infected Cells. <i>Journal of Virology</i> , 1974, 14, 191-197.	1.5	27
256	Polypeptide composition of incomplete influenza virus grown in MDBK cells. <i>Virology</i> , 1975, 65, 418-426.	1.1	26
257	Polarized Apical Targeting Directed by the Signal/Anchor Region of Simian Virus 5 Hemagglutinin-Neuraminidase. <i>Journal of Biological Chemistry</i> , 1997, 272, 27598-27604.	1.6	26
258	Cutaneous immunization: an evolving paradigm in influenza vaccines. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 615-627.	2.4	26
259	Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge. <i>Scientific Reports</i> , 2018, 8, 11193.	1.6	26
260	Preliminary X-ray crystallographic analysis of canine parvovirus crystals. <i>Journal of Molecular Biology</i> , 1988, 200, 209-211.	2.0	25
261	Basolateral Sorting of the HIV Type 2 and SIV Envelope Glycoproteins in Polarized Epithelial Cells: Role of the Cytoplasmic Domain. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 665-675.	0.5	25
262	Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. <i>Vaccine</i> , 2007, 25, 3841-3850.	1.7	25
263	Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice. <i>Frontiers in Immunology</i> , 2019, 10, 3006.	2.2	25
264	Carbohydrate Components of Influenza C Virions. <i>Journal of Virology</i> , 1979, 29, 997-1005.	1.5	25
265	Memory T Cells Generated by Prior Exposure to Influenza Cross React with the Novel H7N9 Influenza Virus and Confer Protective Heterosubtypic Immunity. <i>PLoS ONE</i> , 2015, 10, e0115725.	1.1	25
266	Human Parainfluenza Virus Induces a Type-Specific Protective Immune Response. <i>Journal of Infectious Diseases</i> , 1990, 162, 746-749.	1.9	24
267	Gain-of-function experiments on H7N9. <i>Nature</i> , 2013, 500, 150-151.	13.7	24
268	Virus-Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice. <i>BioMed Research International</i> , 2013, 2013, 1-12.	0.9	24
269	Gain-of-Function Experiments on H7N9. <i>Science</i> , 2013, 341, 612-613.	6.0	24
270	Effects of Filipin on the Structure and Biological Activity of Enveloped Viruses. <i>Journal of Virology</i> , 1977, 24, 883-892.	1.5	24

#	ARTICLE	IF	CITATIONS
271	The sense of the helix of paramyxovirus nucleocapsids. <i>Journal of Molecular Biology</i> , 1972, 65, 167-69.	2.0	23
272	Expression of SV40 receptors on apical surfaces of polarized epithelial cells. <i>Virology</i> , 1992, 190, 393-402.	1.1	23
273	Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain. <i>Virology</i> , 2004, 328, 62-73.	1.1	23
274	Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity. <i>Virology</i> , 2005, 332, 89-101.	1.1	23
275	Mucosal Adjuvants for Influenza Virus-Like Particle Vaccine. <i>Viral Immunology</i> , 2013, 26, 385-395.	0.6	23
276	Microneedle patch delivery of influenza vaccine during pregnancy enhances maternal immune responses promoting survival and long-lasting passive immunity to offspring. <i>Scientific Reports</i> , 2017, 7, 5705.	1.6	23
277	Glycopeptides of Murine Leukemia Viruses I. Comparison of Two Ecotropic Viruses. <i>Journal of Virology</i> , 1979, 31, 1-7.	1.5	23
278	Induction of Immune Responses to SIV Antigens by Mucosally Administered Vaccines. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1469-1476.	0.5	22
279	Proteomic Characterization of Influenza H5N1 Virus-like Particles and Their Protective Immunogenicity. <i>Journal of Proteome Research</i> , 2011, 10, 3450-3459.	1.8	22
280	Oral vaccination with inactivated influenza vaccine induces cross-protective immunity. <i>Vaccine</i> , 2012, 30, 180-188.	1.7	22
281	Permeability properties of the membrane of vesicular stomatitis virions. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1976, 433, 63-74.	1.4	21
282	The complete nucleotide sequence of an infectious clone of porcine parvovirus, strain NADL-2. <i>Virology</i> , 1990, 178, 611-616.	1.1	21
283	Protocatechuic Acid, a Novel Active Substance against Avian Influenza Virus H9N2 Infection. <i>PLoS ONE</i> , 2014, 9, e111004.	1.1	21
284	Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. <i>Scientific Reports</i> , 2015, 5, 11856.	1.6	21
285	Structure of the lipid phase of rauscher murine leukemia virus. <i>Journal of Supramolecular Structure</i> , 1972, 1, 50-54.	2.3	20
286	HIV Envelope Proteins Differentially Utilize CXCR4 and CCR5 Coreceptors for Induction of Apoptosis. <i>Virology</i> , 2001, 285, 128-137.	1.1	20
287	Mutations in the Cytoplasmic Tail of Murine Leukemia Virus Envelope Protein Suppress Fusion Inhibition by R Peptide. <i>Journal of Virology</i> , 2001, 75, 2337-2344.	1.5	20
288	Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1097-1107.	1.7	20

#	ARTICLE	IF	CITATIONS
289	Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses. <i>Scientific Reports</i> , 2017, 7, 40226.	1.6	20
290	Expression of the spleen focus-forming virus envelope gene in a polarized epithelial cell line. <i>Virology</i> , 1988, 164, 547-550.	1.1	19
291	Virus-like particles in MDCK cells persistently infected with Borna disease virus. <i>Virus Research</i> , 1994, 33, 261-268.	1.1	19
292	Skin Immunization with Influenza Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2014, 386, 343-369.	0.7	19
293	A protective role of murine langerin+ cells in immune responses to cutaneous vaccination with microneedle patches. <i>Scientific Reports</i> , 2015, 4, 6094.	1.6	19
294	Replication and plaque assay of influenza C virus in chicken kidney cells. <i>FEMS Microbiology Letters</i> , 1979, 5, 227-230.	0.7	18
295	Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization. <i>Immunobiology</i> , 1999, 200, 21-30.	0.8	18
296	Oligomerization, Secretion, and Biological Function of an Anchor-Free Parainfluenza Virus Type 2 (PI2) Fusion Protein. <i>Virology</i> , 2000, 270, 368-376.	1.1	18
297	Induction of Influenza-Specific Mucosal Immunity by an Attenuated Recombinant Sendai Virus. <i>PLoS ONE</i> , 2011, 6, e18780.	1.1	18
298	Parameters of inhibition of HIV-1 infection by small anionic microbicides. <i>Antiviral Research</i> , 2007, 73, 60-68.	1.9	17
299	Adjuvanted Influenza Vaccine Administered Intradermally Elicits Robust Long-Term Immune Responses that Confer Protection from Lethal Challenge. <i>PLoS ONE</i> , 2010, 5, e10897.	1.1	17
300	Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. <i>Journal of Infectious Diseases</i> , 2015, 212, S398-S403.	1.9	17
301	Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines. <i>Virology</i> , 2016, 489, 141-150.	1.1	17
302	Sequence of the hemagglutinin-neuraminidase gene of human parainfluenza virus type 1. <i>Virus Research</i> , 1990, 16, 107-113.	1.1	16
303	Immunogenicity of Full Length and Truncated SIV Envelope Proteins. <i>Viral Immunology</i> , 1999, 12, 205-215.	0.6	16
304	Mutations in Multiple Domains Activate Paramyxovirus F Protein-Induced Fusion. <i>Journal of Virology</i> , 2004, 78, 8513-8523.	1.5	16
305	Murine Leukemia Virus R Peptide Inhibits Influenza Virus Hemagglutinin-Induced Membrane Fusion. <i>Journal of Virology</i> , 2006, 80, 6106-6114.	1.5	16
306	Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge. <i>Journal of Infectious Diseases</i> , 2018, 218, S545-S552.	1.9	16

#	ARTICLE	IF	CITATIONS
307	Adaptation of Measles Virus to Polarized Epithelial Cells: Alterations in Virus Entry and Release. <i>Virology</i> , 1997, 231, 281-289.	1.1	15
308	Three Membrane-Proximal Amino Acids in the Human Parainfluenza Type 2 (HPIV 2) F Protein Are Critical for Fusogenic Activity. <i>Virology</i> , 2001, 280, 52-61.	1.1	15
309	Mucosal immunity and strategies for novel microbial vaccines. <i>Pediatrics International</i> , 1994, 36, 537-544.	0.2	14
310	Development of a rubella virus DNA vaccine. <i>Vaccine</i> , 1999, 17, 2104-2112.	1.7	14
311	Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses. <i>Journal of Controlled Release</i> , 2016, 233, 208-219.	4.8	14
312	Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine. <i>Scientific Reports</i> , 2017, 7, 17855.	1.6	14
313	Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection. <i>Pharmaceutics</i> , 2019, 11, 188.	2.0	14
314	cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model. <i>Frontiers in Immunology</i> , 2020, 11, 583251.	2.2	14
315	Glycopeptides of Murine Leukemia Viruses III. Glycosylation of env Precursor Glycoproteins. <i>Journal of Virology</i> , 1981, 39, 463-470.	1.5	14
316	Observations on the membrane organization of standard and incomplete influenza grown in MDBK cells. <i>Virology</i> , 1976, 71, 389-394.	1.1	13
317	Structural components of mouse mammary tumor virus III. Composition and tryptic peptides of virion polypeptides. <i>Virology</i> , 1978, 91, 291-304.	1.1	13
318	Analysis of polypeptides in tacaribe virus-infected cells. <i>Virology</i> , 1983, 128, 469-473.	1.1	13
319	Nucleotide sequence analysis of the capsid genes and the right-hand terminal palindrome of porcine parvovirus, strain NADL-2. <i>Virology</i> , 1989, 173, 368-377.	1.1	13
320	Role of the long cytoplasmic domain of the SIV Env glycoprotein in early and late stages of infection. <i>Retrovirology</i> , 2007, 4, 94.	0.9	13
321	Fabrication of microneedle patches with lyophilized influenza vaccine suspended in organic solvent. <i>Drug Delivery and Translational Research</i> , 2021, 11, 692-701.	3.0	13
322	Viral Membranes. , 1979, , 293-407.		13
323	Assembly of lipid-containing viruses. <i>Journal of Supramolecular Structure</i> , 1974, 2, 496-511.	2.3	12
324	Molecular cloning and sequence analysis of the fusion glycoprotein gene of human parainfluenza virus type 2. <i>Virology</i> , 1990, 179, 915-920.	1.1	12

#	ARTICLE	IF	CITATIONS
325	Host cell-dependent lateral mobility of viral glycoproteins. <i>Microbial Pathogenesis</i> , 1990, 9, 375-386.	1.3	12
326	Polarization of viral entry and release in epithelial cells. <i>Seminars in Virology</i> , 1996, 7, 245-253.	4.1	12
327	Comparative analysis of oral delivery systems for live rotavirus vaccines. <i>Journal of Controlled Release</i> , 1996, 41, 237-247.	4.8	12
328	Atypical Fusion Peptide of Nelson Bay Virus Fusion-Associated Small Transmembrane Protein. <i>Journal of Virology</i> , 2005, 79, 1853-1860.	1.5	12
329	Structure and glycosylation of tacaribe viral glycoproteins. <i>Virology</i> , 1982, 123, 452-456.	1.1	11
330	Calmodulin Antagonists Inhibit Human Immunodeficiency Virus-Induced Cell Fusion but Not Virus Replication. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1489-1496.	0.5	11
331	Intracellular Targeting and Assembly of Paramyxovirus Proteins. , 1991, , 457-479.		11
332	Synthesis of Tacaribe virus polypeptides in an in vitro coupled transcription and translation system. <i>Virus Research</i> , 1985, 2, 261-271.	1.1	10
333	The Envelope Glycoprotein of Simian Immunodeficiency Virus Contains an Enterotoxin Domain. <i>Virology</i> , 2000, 277, 250-261.	1.1	10
334	Enhanced cellular immune response against SIV Gag induced by immunization with DNA vaccines expressing assembly and release-defective SIV Gag proteins. <i>Virology</i> , 2003, 309, 272-281.	1.1	10
335	Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-11.	3.0	10
336	A 585-bp deletion found in the spleen focus-forming virus (SFFV) env gene is responsible for the defective intracellular transport of SFFV gp52. <i>Virology</i> , 1992, 188, 181-192.	1.1	9
337	Chapter 1 Viruses as Model Systems in Cell Biology. <i>Methods in Cell Biology</i> , 1994, 43 Pt A, 3-42.	0.5	9
338	Mucosal immunization of CD4+ T cell-deficient mice with an inactivated virus induces IgG and IgA responses in serum and mucosal secretions. <i>Virology</i> , 2005, 331, 387-395.	1.1	9
339	Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. <i>Journal of Experimental Medicine</i> , 2011, 208, 411-411.	4.2	9
340	Effects of Stabilization of the gp41 Cytoplasmic Domain on Fusion Activity and Infectivity of SIVmac239. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1213-1222.	0.5	9
341	Membrane Glycoproteins of Enveloped Viruses. <i>Current Topics in Membranes and Transport</i> , 1978, 11, 233-277.	0.6	8
342	Structural Domains in Vesicular Stomatitis Virus Membrane as Studied by Differential Scanning Calorimetry. <i>Biophysical Journal</i> , 1982, 37, 25-26.	0.2	8

#	ARTICLE	IF	CITATIONS
343	Characterization of a Novel Baboon Virus Closely Resembling Human T-Cell Leukemia Virus. <i>Virology</i> , 1996, 226, 57-65.	1.1	8
344	Coreceptor-Dependent Inhibition of the Cell Fusion Activity of Simian Immunodeficiency Virus Env Proteins. <i>Journal of Virology</i> , 2000, 74, 6217-6222.	1.5	8
345	Enhancement of Immune Responses to an HIVenvDNA Vaccine by a C-Terminal Segment of Listeriolysin O. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 409-420.	0.5	8
346	Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. <i>Virology</i> , 2006, 352, 74-85.	1.1	7
347	Generation of long flavivirus expression cassettes by in vivo recombination and transient dominant selection. <i>Gene</i> , 1994, 149, 193-201.	1.0	6
348	Virus Infection of Epithelial Cells. , 2005, , 769-782.		6
349	Closely Related Influenza Viruses Induce Contrasting Respiratory Tract Immunopathology. <i>PLoS ONE</i> , 2013, 8, e76708.	1.1	6
350	â€œCytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Envâ€• <i>Archives of Virology</i> , 2016, 161, 3011-3018.	0.9	5
351	Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. <i>Vaccines</i> , 2017, 5, 52.	2.1	5
352	Cutaneous vaccination ameliorates Zika virus-induced neuro-ocular pathology via reduction of anti-ganglioside antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2072-2091.	1.4	5
353	Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model. <i>Virology</i> , 2021, 562, 197-208.	1.1	5
354	DIRECTIONAL TRANSPORT OF VIRAL GLYCOPROTEINS IN POLARIZED EPITHELIAL CELLS. , 1981, , 213-231.		5
355	Separation of influenza hemagglutinin tryptic glycopeptides by ion-pair reverse-phase high-performance liquid chromatography (HPLC). <i>Journal of Proteomics</i> , 1980, 3, 61-63.	2.4	4
356	Assembly of G1 and G2 glycoprotein oligomers in Punta Toro virus-infected cells. <i>Virus Research</i> , 1992, 22, 215-225.	1.1	4
357	Distinct Bâ€cell populations contribute to vaccine antigenâ€specific antibody production in a transgenic mouse model. <i>Immunology</i> , 2014, 142, 624-635.	2.0	4
358	Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor. <i>Scientific Reports</i> , 2015, 5, 12321.	1.6	4
359	Isotype of Anti-SIV Responses in Infected Rhesus Macaques and in Animals Immunized by Mucosal Routes. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1389-1389.	0.5	3
360	Lentiviral Vectors Pseudotyped with Envelope Glycoproteins Derived from Human Parainfluenza Virus Type 3. <i>Biotechnology Progress</i> , 2004, 20, 1810-1816.	1.3	3

#	ARTICLE	IF	CITATIONS
361	Enveloped Virus Maturation at Restricted Membrane Domains. , 1984, , 123-129.		3
362	Population Biology, Evolution, and Immunology of Vaccination and Vaccination Programs. American Journal of the Medical Sciences, 1998, 315, 76-86.	0.4	3
363	Structure and variation of the influenza C glycoprotein. Vaccine, 1985, 3, 189-194.	1.7	2
364	Fusogenic Variants of a Noncytopathic Paramyxovirus. Journal of Virology, 2007, 81, 4286-4297.	1.5	2
365	STRUCTURE OF THE SPIKE GLYCOPROTEIN OF INFLUENZA C VIRUS. , 1981, , 263-272.		2
366	VARIATION OF GLYCOSYLATION SITES IN H1N1 STRAINS OF INFLUENZA VIRUS. , 1981, , 253-262.		2
367	Characterization of Glycos-aminoglycans Associated with Rauscher Murine Leukemia Virions. Membrane Biochemistry, 1982, 4, 219-234.	0.6	1
368	A carboxy-terminal mutant Spleen Focus-Forming Virus (SFFV) envelope glycoprotein is transport-competent, but non-leukemogenic. Virus Research, 1992, 26, 57-69.	1.1	1
369	Intradermal Immunization of EBOV VLPs in Guinea Pigs Induces Broader Antibody Responses Against GP Than Intramuscular Injection. Frontiers in Microbiology, 2020, 11, 304.	1.5	1
370	Are long-term influenza vaccines possible and how do we discover them?. Expert Opinion on Drug Discovery, 2021, 16, 213-216.	2.5	1
371	RESTRICTED MOBILITY OF INFLUENZA HEMAGGLUTININ ON HELA CELL PLASMA MEMBRANES. , 1984, , 361-364.		1
372	Vaccines for pandemic influenza. Preface. Current Topics in Microbiology and Immunology, 2009, 333, v-viii.	0.7	1
373	Enhanced immunogenicity of SIV Gag DNA vaccines encoding chimeric proteins containing a C-terminal segment of Listeriolysin O. Virus Research, 2003, 97, 7-16.	1.1	0
374	Influenza prevention during pregnancy. Future Virology, 2016, 11, 171-174.	0.9	0
375	Taiwan's Response to Influenza: A Seroepidemiological Evaluation of Policies and Implications for Pandemic Preparedness. International Journal of Infectious Diseases, 2022, , .	1.5	0